Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 9/20 | 0.47 |
| ▸ | CNR2 | P34972 | 9/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320009 | 1.00 | HSD11B1 (0.56) | HSD11B1KDM4EALDH1A1POLBNPC1 | |
| SCHEMBL2318982 | 0.76 | TAS1R3 (0.57) | KDM4EALDH1A1LMNA | |
| SCHEMBL2317499 | 0.76 | CNR1 (0.62) | HSD11B1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL23626145 | 0.75 | HSD11B1 (0.57) | HSD11B1KDM4EALDH1A1POLBNPC1 | |
| SCHEMBL12809741 | 0.75 | HTT (0.40) | HSD11B1KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2317950 | 0.74 | MEN1 (0.46) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL2317448 | 0.74 | MEN1 (0.46) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL2315580 | 0.74 | MEN1 (0.46) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL1406875 | 0.73 | L3MBTL1 (0.59) | KDM4EALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL13293979 | 0.72 | HSD11B1 (0.67) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928840-A1 | 1H-PYRAZOLE 4-CARBOXYLAMIDES, THEIR PREPARATION AND THEIR USE AS 11BETA-HYDROXYSTEROID DEHYDROGENASE | F. Hoffmann-Roche AG (CH) | 2008-06-11 | — | — | EP | claimed |
| WO-2006106052-A1 | PYRAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | claimed |
| EP-1928840-B1 | 1H-Pyrazole-4-carboxamides, their preparation and their use as 11-beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-1928840-A1 | 1H-PYRAZOLE 4-CARBOXYLAMIDES, THEIR PREPARATION AND THEIR USE AS 11BETA-HYDROXYSTEROID DEHYDROGENASE | F. Hoffmann-Roche AG (CH) | 2008-06-11 | — | — | EP | disclosed |
| US-7345058-B2 | (1-Methyl-5-phenyl-1H-pyrazol-4-yl)-(trans-octahydro-isoquinolin-2-yl)methanone; 11 beta -hydroxysteroid dehydrogenase inhibitor; upregulation of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase); antidiabetic agent; type II diabetes mellitus and metabolic syndrome | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345058-B2 | (1-Methyl-5-phenyl-1H-pyrazol-4-yl)-(trans-octahydro-isoquinolin-2-yl)methanone; 11 beta -hydroxysteroid dehydrogenase inhibitor; upregulation of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase); antidiabetic agent; type II diabetes mellitus and metabolic syndrome | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| WO-2006106052-A1 | PYRAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | disclosed |
| US-20060223852-A1 | Pyrazoles | GILLESPIE PAUL | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223852-A1 | Pyrazoles | GPR119, PDK2, PC | HSD11B1 253/4885KDM4E 4119/4885ALDH1A1 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.